Literature DB >> 19110056

In vitro transscleral iontophoresis of high molecular weight neutral compounds.

Sara Nicoli1, Giulio Ferrari, Marinella Quarta, Claudio Macaluso, Patrizia Santi.   

Abstract

The aim of the work was to study in vitro, across porcine and human sclera, the effect of transscleral iontophoresis on the permeation of high molecular weight neutral dextrans, chosen as models of high molecular weight drugs. Iontophoretic (anodal and cathodal) and passive permeation experiments were performed through pig sclera using acetaminophen (MW=151Da) and labelled dextrans (MW between 4.4kDa and 120kDa) as neutral model compounds. Anodal iontophoresis of 120kDa dextran was also performed on human sclera. Membrane charge was also determined at different pH values. Both human and pig sclera show a net negative charge at pH 7.4 and in the presence of current an electroosmotic convective solvent flow in the anode-to-cathode direction takes place. During anodal iontophoresis, the electroosmotic flow (whose entity resulted approximately 4 microlcm(-2)h(-1)) was able to increase 2-6.5 times the transscleral flux of dextrans. Transscleral iontophoresis can be useful for enhancing the transport across the sclera of high molecular weight compounds, even though neutral. This result suggests a possible application of this technique for the non-invasive administration of new biotech drugs for the treatment of the posterior segment eye diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110056     DOI: 10.1016/j.ejps.2008.11.012

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  9 in total

1.  Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Control Release       Date:  2012-01-27       Impact factor: 9.776

Review 2.  The parameters of the porcine eyeball.

Authors:  Irene Sanchez; Raul Martin; Fernando Ussa; Ivan Fernandez-Bueno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-02       Impact factor: 3.117

3.  Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules.

Authors:  Sarah Molokhia; Kongnara Papangkorn; Charlotte Butler; John W Higuchi; Balbir Brar; Balamurali Ambati; S Kevin Li; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2020-03-05       Impact factor: 2.671

4.  A Hydrogel Ionic Circuit Based High-Intensity Iontophoresis Device for Intraocular Macromolecule and Nanoparticle Delivery.

Authors:  Fan Zhao; Shan Fan; Deepta Ghate; Svetlana Romanova; Tatiana K Bronich; Siwei Zhao
Journal:  Adv Mater       Date:  2021-12-08       Impact factor: 30.849

5.  Influence of drug lipophilicity on drug release from sclera after iontophoretic delivery of mixed micellar carrier system to human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-11-13       Impact factor: 3.534

6.  Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.

Authors:  He Wen; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-12-04       Impact factor: 3.534

7.  Iontophoretic transport of charged macromolecules across human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  Int J Pharm       Date:  2010-01-05       Impact factor: 5.875

Review 8.  Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.

Authors:  Hyeong Min Kim; Se Joon Woo
Journal:  Pharmaceutics       Date:  2021-01-15       Impact factor: 6.321

9.  Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery.

Authors:  Giselly Almeida Dos Santos; Ricardo Ferreira-Nunes; Luciana Facco Dalmolin; Ana Carolina Dos Santos Ré; Jorge Luiz Vieira Anjos; Sebastião Antônio Mendanha; Carolina Patrícia Aires; Renata F V Lopez; Marcilio Cunha-Filho; Guilherme M Gelfuso; Taís Gratieri
Journal:  Sci Rep       Date:  2020-11-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.